In a series of regulatory wrist-slaps now made public, the FDA has taken three manufacturers to task over record request ...
Johnson & Johnson is gearing up to expand the commercial reach of Caplyta after scoring a second phase 3 victory in bipolar ...
Merck KGaA just secured an FDA approval for its new once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, ...
ImmuniyBio is eyeing a move up the non-muscle invasive bladder cancer (NMIBC) treatment line for its immunotherapy Anktiva. ...
Following a back-and-forth with the Pentagon this year, contracting juggernaut WuXi AppTec appears to have largely evaded its ...
Summit Therapeutics is gearing up for ivonescimab’s high-stakes FDA decision without its chief commercial officer (CCO) ...
Vertex has decided to lay off 78 employees at Crinetics Pharmaceuticals following its $10 billion acquisition of the ...
In a new readout of 12-month data, Veradermics' oral minoxidil delivered the best hair growth data of its phase 3 program so ...
The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results